CIPHER PHARMACEUTICALS INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8.795 CAD | -0.28% |
|
-3.14% | +58.75% |
| Mar. 15 | Transcript : Cipher Pharmaceuticals Inc., Q4 2023 Earnings Call, Mar 15, 2024 | |
| Mar. 14 | Tranche Update on Cipher Pharmaceuticals Inc.'s Equity Buyback Plan announced on November 15, 2023. | CI |
Presentation Operator MessageOperator (Operator)Good morning, ladies and gentlemen, thank you ...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Cipher Pharmaceuticals Inc. is a Canada-based specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products either directly in Canada or indirectly through partners in Canada, the United States and South America. Its Dermatology products include Actikerall, Epuris, Ozanex and Vaniqa. Its Hospital Acute Care products include Aggrastat and Brinavess. Its Out-Licensed products include Absorica, ConZip and Lipofen. The Company is also focused on building a portfolio of prescription medicines that serve unmet medical needs. The Company's product pipeline development programs including MOB-015, DTR-001, and CF-101. The Company's subsidiaries include Cipher US Holdings Inc., Cipher US Holdco LLC, and Cipher Pharmaceuticals US LLC.
Sector
Pharmaceuticals
Calendar
2024-05-08
- Q1 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
8.795
CAD
Average target price
7.617
CAD
Spread / Average Target
-13.40%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +58.75% | 154M | |
| +27.97% | 672B | |
| +23.58% | 550B | |
| -7.02% | 351B | |
| +14.85% | 317B | |
| +6.25% | 292B | |
| +2.96% | 211B | |
| -0.41% | 203B | |
| -10.02% | 194B | |
| -11.81% | 144B |
- Stock Market
- Equities
- CPH Stock
- News Cipher Pharmaceuticals Inc.
- Transcript : Cipher Pharmaceuticals Inc., Q3 2022 Earnings Call, Nov 11, 2022
